Sevenfact Kit
FDA Label NDC 71127-2000

● Serious arterial and venous thrombotic events may occur following administration of SEVENFACT^®. [See Warnings and Precautions (5.1)]

● Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive SEVENFACT^®.

● Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. 

Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency.

For intravenous use after reconstitution only.

• Dose and duration of treatment depend on the location and severity of the bleeding, need for urgent hemostasis, frequency of administration, and known patient responsiveness to FVIIa-containing bypassing agents during prior bleeding events. Treatment with SEVENFACT should be initiated as soon as a bleeding event occurs. 
  
• The dose, frequency, and duration of SEVENFACT therapy should be based on the patient’s clinical response and hemostasis evaluation. 
  
• The use of laboratory assessment(s) of coagulation (PT/INR, aPTT, FVII:C) does not necessarily correlate with or predict the hemostatic effectiveness of SEVENFACT.
  
• Maximum tolerated doses have not been determined for SEVENFACT, and cumulative daily doses greater than 900 mcg/kg, which may be associated with greater risk of thromboembolic complications, have not been studied. 
  
• Dose adjustment may be required if the patient has received other procoagulant therapies prior to treatment with SEVENFACT.

Based on the clinical trial program for SEVENFACT, the recommended initial dose should be adjusted based on the criteria provided in Table 1.

Table 1       Dosing for Treatment and Control of Bleeding

Type of Bleeding	Dosing Regimen Recommendation	Duration of Therapy
Mild and Moderate	75 mcg/kg repeated every 3 hours until hemostasis is achieved	Continue therapy to support healing and prevent recurrent hemorrhage after hemostasis to maintain the hemostatic plug.
Joint, superficial muscle, soft tissue and mucous membranes.	or	The site and severity of bleeding should determine therapy duration.
	Initial dose of 225 mcg/kg. If hemostasis is not achieved within 9 hours, additional 75 mcg/kg doses may be administered every 3 hours as needed to achieve hemostasis
	Consider alternative treatments if successful control of bleeding does not occur within 24 hours of the first administration of SEVENFACT
	Consider the following factors when choosing the initial dose of SEVENFACT: The severity and site of bleeding and need for urgent hemostasis. Frequency of administration. Known patient responsiveness to FVIIa-containing bypassing agents during prior bleeding events.
Severe Life or limb threatening hemorrhage, iliopsoas and deep muscle with neurovascular injury, retroperitoneum, intracranial, or gastrointestinal.	225 mcg/kg initially, followed if necessary 6 hours later with 75 mcg/kg every 2 hours until hemostasis is achieved Subsequent Dosing: After achieving hemostasis, base the decision for dosing on clinical assessment and the type of bleeding. Consider the risk of thrombosis with subsequent dosing after achieving hemostatic efficacy.	Continue therapy to support healing and prevent recurrent hemorrhage. The site and severity of bleeding and the use of other procoagulant therapies should determine therapy duration.
Patients should seek immediate medical care if signs or symptoms of severe bleeding occur in the home setting.

• Follow the procedures below for reconstitution of SEVENFACT.
  
• Calculate the amount of SEVENFACT required and select the appropriate SEVENFACT packages containing the matching pre-filled syringe of sterile Water for Injection, and the vial adapters.
  
• Reconstitute each vial with the pre-filled syringe provided with each vial of SEVENFACT.

Overview of SEVENFACT Package

Lyophilized Powder Drug Vial



Lyophilized Powder Drug Vial (Recombinant 01)

Figure 1     Vial with SEVENFACT lyophilized powder

Syringe Plunger Rod                                                 Pre-filled syringe with Diluent



Syringe Plunger Rodpre-filled Syringe With Diluent (Recombinant 02)

Figure 2     Syringe plunger rod and pre-filled syringe with Water for Injection diluent

Vial Adapters* and Packaging

1 mg vial adapter                                           5 mg vial adapter



Vial Adapters* And Packaging (Recombinant 03)

Figure 3     SEVENFACT 1 mg vial adapter and SEVENFACT 5 mg vial adapter

*Note: Each SEVENFACT kit will contain only one vial adapter.

The instructions below serve as a general guideline for reconstitution of SEVENFACT.

Reconstitution:

1. Based on the prescribed dose, take out the number of SEVENFACT kits (each kit containing one vial of SEVENFACT powder and one pre-filled Water for Injection diluent syringe with one vial adapter for needleless reconstitution), an infusion set (not supplied in the kit) and an alcohol swab (not supplied in the kit). Check the expiration date on the side of the box(es) for the SEVENFACT kit(s).

2. Always use aseptic technique. Wash your hands with soap and water and dry them using a clean towel or air dry.

3. Take out the contents of one kit and one alcohol swab. Place items on a clean surface.

4. Inspect all contents of the kit. Make sure each vial has a matching colored syringe.

5. Bring SEVENFACT (lyophilized powder) and the specified pre-filled syringe (diluent) to room temperature. The specified volume of diluent corresponding to the amount of SEVENFACT is as follows:

1 mg (1000 micrograms) vial + 1.1 mL Water for Injection diluent in pre-filled syringe

5 mg (5000 micrograms) vial + 5.2 mL Water for Injection diluent in pre-filled syringe 

6. Remove the plastic cap from the SEVENFACT vials to expose the central portion of the rubber stopper. Cleanse the rubber stoppers with an alcohol swab and allow to dry prior to use.

7. Peel back the protective paper from the vial adapter. Do not remove the vial adapter from the package.

8. Place the SEVENFACT vial on a flat surface. While holding the vial adapter package, place the vial adapter over the SEVENFACT vial and press down firmly on the package until the vial adapter spike breaks through the rubber stopper.

9. Lightly squeeze the plastic cover and lift up to remove it from the vial adapter. Note: the 5 mg vial adapter may not sit flat against the vial, but it is fully functional.

10. Remove the syringe cap from the pre-filled syringe by holding the syringe body with one hand to unscrew the syringe cap (turn to the left).

11. While holding the edges of the vial adapter, screw on the pre-filled syringe (turn to the right) a few turns until it starts to tighten.

12. Insert the plunger rod into the syringe, then screw a few turns (turn to the right) so that the plunger rod is attached to the gray rubber stopper in the syringe.

13. Push the plunger rod to slowly inject all the diluent into the vial. Keep the plunger rod pressed down and swirl the vial gently until the powder is dissolved.

14. The reconstituted solution is clear to slightly opaque. All powder must be mixed with no particles floating in the liquid. 

15. Without withdrawing any drug back into the syringe, unscrew the syringe from the vial adapter (turn to the left) until it is completely detached. 

16. Withdraw the liquid drug from the vial(s), using an infusion syringe provided by the pharmacy; the syringe should be large enough to hold the prescribed dose.

17. The reconstituted solution should be stored in the vial at room temperature, but can be stored between 36^oF to 86^oF (2^oC to 30^oC) for up to 4 hours after reconstitution. After reconstitution with the specified volume of diluent, each vial contains approximately 1 mg per mL SEVENFACT (1000 micrograms per mL).

For Intravenous Use Only.

• Visually inspect the reconstituted solution for particulate matter and discoloration prior to administration. Do not use if particulate matter or discoloration is observed.
  
• Do not freeze reconstituted solution or store it in a syringe.
  
• SEVENFACT must be infused within 4 hours after reconstitution.
  
• SEVENFACT should be infused over 2 minutes or less as a bolus intravenous infusion.
  
• Do not mix with other infusion solutions.
  
• Any unused solution should be discarded 4 hours after reconstitution.

SEVENFACT is a white to off-white lyophilized powder for reconstitution in a colorless solution for injection. It is supplied in single-dose vial sizes containing 1 mg or 5 mg of coagulation factor VIIa (recombinant)-jncw. 

The diluent for reconstitution of SEVENFACT is supplied in single-dose prefilled glass syringes containing 1.1 mL or 5.2 mL sterile Water for Injection. It is a clear colorless solution. 

After reconstitution with the appropriate volume of Water for Injection diluent, each mL of SEVENFACT contains 1 mg per mL of coagulation factor VIIa (recombinant)-jncw (1,000 micrograms per mL).

SEVENFACT is contraindicated in

• known allergy to rabbits or rabbit proteins. Exposure to SEVENFACT in these patients can result in severe hypersensitivity reaction. 
  
• patients with severe hypersensitivity reaction to SEVENFACT or any of its components. Exposure to SEVENFACT in these patients can result in severe hypersensitivity reaction. 

• There is limited information about the safety of SEVENFACT in patients with a history of arterial or venous thromboembolic disease, because such patients were excluded from SEVENFACT trials. Serious arterial and venous thrombotic reactions can occur with SEVENFACT. Such reactions have been reported in clinical trials and post-marketing surveillance with a similar class of products. Neither arterial nor venous thrombotic events have been reported in SEVENFACT clinical trials.
  
• The following patients may have increased risk of thromboembolic events with use of SEVENFACT:
  ● History of congenital or acquired hemophilia receiving concomitant treatment with aPCC/PCC (activated or non-activated prothrombin complex) or other hemostatic agents
  ● History of atherosclerotic disease, coronary artery disease, cerebrovascular disease, crush injury, septicemia, or thromboembolism. 
  
• Monitor patients who receive SEVENFACT for the development of signs and symptoms of activation of the coagulation system or thrombosis. When there is laboratory confirmation of intravascular coagulation or presence of clinical thrombosis, reduce the dose of SEVENFACT or stop treatment, depending on the patient’s condition.

• No hypersensitivity reactions have been reported in SEVENFACT trials; however, hypersensitivity reactions, including anaphylaxis, can occur with SEVENFACT. Symptoms may include hives, itching, rash, difficulty breathing, swelling around the mouth and throat, tightness of the chest, wheezing, dizziness or fainting, and low blood pressure. In the event of hypersensitivity reactions, patients should discontinue treatment and seek immediate medical attention.
  
• Patients with known IgE-based hypersensitivity to casein may be at higher risk of hypersensitivity reactions. Should signs or symptoms of hypersensitivity occur, treatment should be discontinued. Subsequent treatment with SEVENFACT should be based on a thorough assessment of the risks and benefits.

• In the studies performed, no patients tested positive for neutralizing antibodies. Nevertheless, neutralizing antibodies may occur with the use of SEVENFACT. If treatment with SEVENFACT does not result in adequate hemostasis, then suspect development of neutralizing antibody as the possible cause and perform testing as clinically indicated. 
  
• Neutralizing antibodies to other Factor VIIa-containing products have been observed in congenital Factor VII-deficient patients. SEVENFACT has not been studied in this patient population. [See limitation of use statement under Indications and Usage (1)].

Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) do not correlate with clinical response to SEVENFACT treatment.

The most common adverse reactions (incidence ≥1%) reported in clinical trials for SEVENFACT were headache, dizziness, infusion-site discomfort, infusion-site hematoma, infusion-related reaction, and fever.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two studies of SEVENFACT in patients with Hemophilia A or B with or without inhibitors, 42 subjects (27 subjects in Study 1 and 15 subjects in Study 2) have been exposed to SEVENFACT.

Study 1: The safety of SEVENFACT has been evaluated in a safety and efficacy study of 27 subjects with Hemophilia A or B with inhibitors, which included treatment of 468 bleeding episodes. As described in Table 2, a total of seven adverse reactions were observed in two subjects (7.4%) treated with SEVENFACT. One episode of fever occurred in a 12-year-old subject, lasted two days, and was managed symptomatically.

Study 2: In a study with 15 subjects evaluating the safety and pharmacokinetics of three escalating doses of SEVENFACT (25 mcg/kg, 75 mcg/kg and 225 mcg/kg), a total of three (20%) subjects experienced four adverse reactions (Table 2).

One subject developed an infusion reaction immediately following the infusion of the first dose of 75 mcg/kg; the reaction lasted 45 minutes. Signs and symptoms included flushing, chest tightness, shakiness, transient tachycardia, and mild hypotension. Symptoms resolved without any intervention and did not recur with subsequent administration at 225 mcg/kg dose.

Adverse reactions reported in the two clinical studies are shown in Table 2.

In Study 1, two out of 27 subjects had a positive screening assay for anti-SEVENFACT antibody at baseline, prior to exposure to SEVENFACT, and at follow-up visits. One of these two subjects had a transient SEVENFACT antibody with an additional confirmatory test for anti-SEVENFACT antibody, which was confirmed as non-neutralizing.

In Study 2, five of 15 subjects tested positive for anti-SEVENFACT antibody using a screening assay. The confirmatory assay was negative for all subjects at all time points.

No subject developed anti-rabbit milk protein antibodies during treatment with SEVENFACT.

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibodies is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SEVENFACT with the incidence of antibodies to other products may be misleading.

Clinical experience with pharmacologic use of FVIIa-containing products indicates an elevated risk of serious thrombotic events when used simultaneously with activated prothrombin complex concentrates.

Risk Summary

There are no adequate and well-controlled studies using SEVENFACT in pregnant women to determine whether there is a drug-associated risk. Animal studies evaluating the embryo-fetal teratogenic potential of SEVENFACT have not been conducted. It is unknown whether SEVENFACT can cause fetal harm when administered to a pregnant woman or can affect fertility.

In the U.S. general population, the estimated background risks of major birth defect and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

Risk Summary

There is no information regarding the presence of SEVENFACT in human milk, the effect on the breastfed infant, and the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SEVENFACT and any potential adverse effects on the breastfed infant from SEVENFACT or from the underlying maternal condition.

Risk Summary

In Study 1, male patients cautioned to avoid sexual activity without condoms received SEVENFACT for the treatment of bleeding episodes. No pregnancies from sexual partners were reported. The relative benefits of SEVENFACT should be weighed against any potential risk arising from exposure in sexually active patients.

All clinical studies of SEVENFACT were performed on males, as males are predominantly affected with the congenital form of hemophilia. No adverse effects on the mating index, fertility, or conception rate were observed following administration of SEVENFACT at dose levels up to 13-fold higher than the highest recommended human dose in healthy male rats prior to and during cohabitation with healthy untreated female rats [See Carcinogenesis, Mutagenesis, Impairment of Fertility (13.1)].

Limited clinical data for SEVENFACT in the pediatric population were collected in an adult and adolescent study (Study 1). A total of 5 subjects aged ≥12 to <18 years of age (range 13-17 years) were dosed with SEVENFACT. These 5 subjects were treated for a total of 79 bleeding episodes (all mild or moderate) that occurred while subjects were still under 18 years of age. Hemostatic efficacy in this subgroup (n=5) was comparable to efficacy observed in the overall population [See Clinical Studies (14)].

Safety and effectiveness of SEVENFACT in patients >65 years of age have not been evaluated in clinical trials. The presence of age-related comorbidities and the attendant risks associated with thrombotic and thromboembolic events should be considered when administering SEVENFACT to patients older than 50 years of age.

There have been no reports of overdosage with SEVENFACT. Doses greater than 900 mcg/kg/day have not been studied. Doses greater than 900 mcg/kg per 24 hours may be associated with an increased risk of thromboembolic events. 

SEVENFACT is a sterile, white to off-white lyophilized powder in a single-use vial containing either 1 mg or 5 mg of coagulation factor VIIa (recombinant)-jncw as the active ingredient. SEVENFACT is to be reconstituted with Sterile Water for Injection in a pre-filled syringe supplied with the product. The reconstituted product is a clear to slightly opaque solution of coagulation factor VIIa (recombinant)-jncw at a concentration of 1 mg of protein per mL with a pH of approximately 6.0. SEVENFACT is formulated with arginine, isoleucine, citrate, glycine, lysine and polysorbate 80. It does not contain any antimicrobial preservatives nor human or bovine plasma-derived proteins.

The active ingredient in SEVENFACT, activated coagulation Factor VII, is a glycoprotein of 406 amino acids with a molecular weight of approximately 50 kilodaltons. The amino acid sequence of activated coagulation Factor VII is identical to that of human plasma-derived Factor VIIa. It is >99% pure with a nominal specific activity of 45,000 IU/mg of protein when tested against the World Health Organization international standard for human Factor VIIa activity.

SEVENFACT is produced by recombinant DNA technology using genetically engineered rabbits into which the DNA coding sequence for human Factor VII has been introduced. Human Factor VII is expressed in the rabbit mammary gland and secreted into the milk. During purification and processing, Factor VII is enzymatically converted to activated Factor VII. The manufacturing process of SEVENFACT includes specific steps to reduce impurities. SEVENFACT may contain trace amounts of rabbit proteins. The purification process also includes steps that are validated to inactivate or remove viruses, such as Xenotropic murine leukemia virus (X-MuLV), bovine viral diarrhea virus (BVDV), Pseudorabies virus (PRV), Feline Calicivirus (FCV), and Porcine Parvovirus (PPV).

The active ingredient in SEVENFACT is a recombinant analog of human Factor VIIa, a vitamin K-dependent coagulation factor. In the presence of both calcium and phospholipids, Factor VIIa in a complex with tissue factor (TF) activates Factor X to Factor Xa, directly bypassing the reactions that require Factor VIII or Factor IX. Activation of Factor X to Factor Xa initiates the common pathway of the coagulation cascade in which prothrombin is activated to thrombin, which then converts fibrinogen to fibrin to form a hemostatic plug, thereby achieving clot formation at the site of hemorrhage (hemostasis). This process may also occur in the absence of TF on the surface of activated platelets.

Laboratory assessment of coagulation does not necessarily correlate with or predict the hemostatic effectiveness of SEVENFACT.

SEVENFACT demonstrated a dose and concentration-dependent pharmacodynamics effect on the coagulation system, including shortening of the activated partial thromboplastin time (aPTT) and the prothrombin time (PT), and increasing the thrombin generation with platelets (TGT) and the maximum clot firmness (ROTEM-FIBTEM test).

Pharmacokinetic (PK) evaluation was conducted in a Phase 3, global, multicenter, prospective, open-label, randomized, crossover study (Study 1). PK analysis was conducted in subjects after a single intravenous administration of either 75 mcg/kg or 225 mcg/kg of SEVENFACT as a bolus injection. 

Five minutes after infusion, plasma SEVENFACT levels were 566.2 ng/mL and 2440.6 ng/mL for 75 mcg/kg and 225 mcg/kg dose groups respectively. Observed plasma concentration-time profiles show a biexponential decay from the maximal concentration to return to baseline approximately 8 hours post-administration. Exposure PK parameters C_max and AUC_0-inf suggested dose dependence over the ranges studied. The clearance of SEVENFACT were 8.0 L/h and 5.8 L/h for 75 mcg/kg and 225 mcg/kg dose levels respectively. Half-life time is approximately 1.6 hours (1.4 hours for 225 mcg/kg and 1.7 hours for 75 mcg/kg utilizing Non-Compartmental Analysis). 

Studies in animals to evaluate the potential effect of SEVENFACT on carcinogenesis or mutagenesis were not conducted. Male rats intravenously infused with SEVENFACT at 0.1, 0.3, 1 and 3 mg/kg/day (up to 13-fold higher than the highest recommended human dose of 225 mcg/kg), beginning 28 days before cohabitation and during cohabitation did not display adverse effects for the mating index, fertility, or conception rate. Comparing animals administered vehicle to animals administered SEVENFACT, there were no differences in sperm motility, morphology, or concentration.

The no observed adverse effect level (NOAEL) in 28-day repeat-dose toxicity studies in male Sprague-Dawley rats and Cynomolgus monkeys was 1 mg/kg/day, which is 4-fold higher than the highest recommended human dose. Anti-drug antibody formation was observed by Day 29 in both animal species. The NOAEL in a 13-week repeat-dose toxicity study in male and female Cynomolgus monkeys was 1 mg/kg/day. Anti-drug antibody formation was observed in all animals by Day 28. Antibody presence was not associated with any adverse effects in either animal species.

The efficacy and safety of SEVENFACT for treatment of bleeding episodes was evaluated in Study 1. Twenty-seven subjects with hemophilia A or B with inhibitors were treated for 468 bleeding events, of which 465 were mild or moderate and three were severe bleeding events. Of the 27 subjects, 5 subjects were 12 to < 18 years of age and they experienced 79 bleeding events. The study was a global, multicenter, randomized, open-label, crossover of two initial dose regimens. Subjects were male, predominantly Caucasian (93%), with a mean age of 31 (range 12-54) years and median of 10 (3-50) bleeding episodes in six months prior to study enrollment. Overall, target joint(s)/bleeding site(s) were reported in 63% of subjects at study entry. 

All doses of SEVENFACT were given at home or in clinic.  

Of the 468 bleeding events in diverse anatomic locations that were treated, 82% were spontaneous and the remaining (18%) were traumatic bleeding episodes; 465 were mild or moderate bleeding events and 3 were severe (refer to Table 5). The majority (98%) of bleeding events were treated at home, with 88% treated within one hour of recognition of bleeding.

Treatment Regimens for Mild or Moderate Bleeding Episodes

For mild to moderate bleeding episodes, subjects were randomized to one of two initial dose regimens of SEVENFACT:

• 75 mcg/kg followed by subsequent doses of 75 mcg/kg every 3 hours as necessary to achieve hemostatic efficacy. A total of 8 administrations were allowed in this dose regimen.
  
• 225 mcg/kg dose followed 9 hours later with 75 mcg/kg doses every 3 hours as necessary to achieve hemostatic efficacy. A total of 6 administrations were allowed in this dose regimen.

Treatment with SEVENFACT was discontinued when bleeding persisted 24 hours after the first administration of SEVENFACT. 

In Study 1, subjects were randomized to one of two initial dosing regimens and continued on the dose regimen for three months, after which the subjects were crossed over to the other dose regimen for three months.

Treatment Regimens for Severe Bleeding Episodes

Patients in the randomized study who experienced a severe bleed were administered the initial dose of 225 mcg/kg SEVENFACT at home, and were required to receive subsequent treatments at 75 mcg/kg every two hours in a hospital or hemophilia treatment center (HTC), if additional doses were considered necessary for treatment of ongoing bleeding. If response to treatment after the first or any subsequent administrations of study drug were satisfactory (i.e., efficacy assessment was rated as “good” or “excellent”), the dosing interval was changed from two hours to three hours for 1 to 2 days, after which the interval could be increased to 4 to 12 hours, depending on the severity of the bleeding episode, for as long as needed.

Bleeding Assessment

The primary endpoint of the study was successful treatment of mild or moderate bleeding episode at 12 hours after initial SEVENFACT dose administration. Success was defined by a combination of the following: subject’s response of “good” or “excellent” using a 4-point hemostatic efficacy scale (presented in Table 4), no further treatment with SEVENFACT beyond the 12-hour time point, no other hemostatic treatment needed for the bleeding episode, no administration of blood products, and no increase in pain beyond 12 hours. 

Table 4       The 4-point Hemostatic Efficacy Scale Used to Assess Efficacy of Treatment

Patient and/or *HCP Evaluation	Therapeutic Response	Description
None	Lack of hemostatic efficacy	No noticeable effect of the treatment on the bleeding or worsening of subject’s condition. Continuation of treatment with the study drug was needed.
Moderate	Lack of hemostatic efficacy	Some effect of the treatment on the bleeding was noticed (e.g., pain decreased, or bleeding signs improved) but the bleeding continued and required continued treatment with the study drug.
Good	Hemostatic efficacy	Symptoms of the bleeding (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.
Excellent	Hemostatic Efficacy	Full relief of pain and cessation of objective signs of the bleeding (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage). No additional infusion of study drug was required.
*Healthcare provider

The primary efficacy analysis compared hemostatic efficacy of each dosing regimen with a prespecified objective performance criterion (OPC) of 55%. This OPC was based on historical data for hemostatic efficacy of bypassing agents. The study was powered to detect a 15% improvement over OPC for each dosing regimen. Results of the primary efficacy analysis are shown in Table 5. 

Of the 465 mild or moderate bleeding episodes, 17 bleeding events were not evaluable due to missing a hemostatic efficacy assessment at 12 hours.

The proportion of mild or moderate bleeding events with hemostatic efficacy at 12 hours was 82% in the 75 mcg/kg dose regimen group and was 91% in the 225 mcg/kg dose regimen group.

Hemostatic efficacy was evaluated in 79 bleeding events in the five adolescent subjects: for the 75 mcg/kg dose regimen, hemostatic efficacy was 93% (95% CI; 81%- 99%) and for the 225 mcg/kg dose regimen, it was 91% (95% CI; 77%-98%), with the confidence intervals given by the Clopper-Pearson exact method.

Table 5       Efficacy of SEVENFACT at 12 Hours for Treatment and Control of Mild or Moderate Bleeding Episodes

	75 mcg/kg (N=25)1	225 mcg/kg (N=25)1	Overall (N=27)1
Number of bleeding episodes	252	213	465
Number of bleeds with hemostatic efficacy	197 (78.1%)	188 (88.2%)	385 (82.8%)
Number of failures	44 (17.4.%)	19 (8.9%)	63 (13.5%)
Number of missing	11 (4.3%)	6 (2.8%)	17 (3.7%)
Proportion of bleeds with hemostatic efficacy [95% CI]2	82% [72%, 91%]	91% [84%, 98%]	86% [78%, 93%]
p-value3	<0.001	<0.001
1 N in the column header indicates number of subjects who had at least 1 bleeding episode treated with a given dose of study drug. 2 Analysis was based on data as observed. No missing value imputation was made. 3 p-value from 1-sided normal approximation test of H0: p ≤0.55, where p is the true proportion of successfully treated mild or moderate bleeding episodes at 12 hours, with adjustment for the correlation among bleeding episodes for a given subject. The null hypothesis of hemostatic efficacy less than or equal to 55% was rejected. Note: Stratified by actual treatment regimen at the time of the bleeding episode. CI = confidence interval.

The median and mean (SD) numbers of administrations per mild or moderate bleeding episode were 2.0 and 2.5 (1.75) for the 75 mcg/kg dose regimen and 1.0 and 1.4 (0.96) for the 225 mcg/kg dose regimen. 

The median time to attain good or excellent assessment by the patient was 6 hours for the 75 mcg/kg dose regimen and 3 hours for the 225 mcg/kg dose regimen.

There were 3 severe bleeding episodes, of which one was a traumatic intramuscular bleeding episode and two were spontaneous bleeding episodes in the right hip and kidney. Hemostasis was achieved at 12 hours in the three severe bleeding events. One severe bleed was treated with three 225 mcg/kg doses administered every 6 hours, which was a deviation from the study protocol-specified dosing. The remaining 2 subjects were treated with 1 and 5 doses of SEVENFACT respectively.

No subject received any alternative therapy prior to 24 hours. In addition, 97.6% of bleeding episodes treated with the 75 mcg/kg dose regimen, and 99.5% of bleeding episodes treated with the 225 mcg/kg dose regimen, did not require treatment with alternative bypassing agents.

How Supplied

• SEVENFACT [coagulation factor VIIa (recombinant)-jncw], is supplied as a room temperature stable, white to off-white, lyophilized powder in single-use vials, one vial per carton. The diluent for reconstitution of SEVENFACT is Water for Injection supplied as a clear colorless solution in a pre-filled syringe.
  
• Single 1 or 5 mg vials of SEVENFACT are available in packages as indicated below.

Table 7       SEVENFACT Presentations

Presentation	Cap Color Indication	NDC Number	Contents
1 mg per vial	Yellow	NDC 71127-1000-1	One 1 mg SEVENFACT single-dose vial [NDC 71127-1100-1] One pre-filled syringe containing 1.1 mL of Sterile Water for Injection [NDC 71127-1200-1] One 13 mm vial adapter with 5 micron filter
5 mg per vial	Purple	NDC 71127-5000-1	One 5 mg SEVENFACT single-dose vial [NDC 71127-5100-1] One pre-filled syringe containing 5.2 mL of Sterile Water for Injection [NDC 71127-5200-1] One 20 mm vial adapter with 5 micron filter

• The SEVENFACT vials are made of glass, closed with a bromobutyl rubber stopper (not made with natural rubber latex), and sealed with an aluminum cap.
  
• The pre-filled diluent syringes are made of glass, with a siliconized bromobutyl rubber plunger (not made with natural rubber latex).

Storage and Handling

• Prior to reconstitution, the SEVENFACT kit should be stored at room temperature but can be stored between 36°F to 86°F (2°C to 30°C), protected from light in the product package. Do not freeze.
  
• After reconstitution, SEVENFACT should be stored at room temperature but can be stored between 36°F to 86°F (2°C to 30°C), for up to 4 hours. Do not freeze or store in syringes.

Advise patients:

• to read the FDA-approved patient labeling (Patient Product Information and Instructions for Use).
  
• about the early signs of hypersensitivity reactions and to seek medical help if the following occur:
  - Hives, itching, rash, difficulty breathing, swelling around the mouth and throat, tightness of the chest, wheezing, dizziness or fainting, low blood pressure, or other symptoms of anaphylaxis.
  
• about the signs of thrombosis and to seek medical help if the following occur:
  - New-onset swelling and pain in the limbs or abdomen, new-onset chest pain, shortness of breath, loss of sensation or motor power, or altered consciousness or speech.

Version: 1

License Number: 2061

“SEVENFACT” is a trademark of LFB S.A.

PATENT Information: https://hemabiodup.wpengine.com/patents/

For information contact:
Call: 855.718.HEMA (4362)
Fax: 855.721.HEMA (4362)
Email: [email protected]

Manufactured by:
Laboratoire Français du Fractionnement et des Biotechnologies S.A. (LFB S.A.)
Les Ulis, 91940
France

U.S. License Number: 2061

Distributed by:
HEMA Biologics
Louisville, KY 40241

SEVENFACT
coagulation factor VIIa (recombinant)-jncw 
1 mg

Sevenfactcoagulation Factor Viia (recombinant)-jncw 1 mg (Recombinant 1c)

SEVENFACT
coagulation factor VIIa (recombinant)-jncw 
5 mg

Sevenfactcoagulation Factor Viia (recombinant)-jncw 5 mg (Recombinant 1d)